300841.SZ Overview

Company Profile

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, and operation of biological products in China. It offers freeze-dried human rabies vaccines; ACYW135 meningococcal polysaccharide vaccine. The company was founded in 2004 and is based in Chengdu, China.

Related stocks

300294.SZ

300294.SZ • China

14.88 CNY

1.12B USD 1Y -40.6%

9887.HK

9887.HK • China

LEADS BIOLABS-B

45.56 HKD

1.15B USD 1Y -37.5%

688177.SS

688177.SS • China

BIO THERA SOLUTIONS LTD

19.3 CNY

1.2B USD 1Y -31.6%

688366.SS

688366.SS • China

SHANGHAI HAOHAI BIOLOGICAL TECH

30.77 CNY

1.03B USD 1Y -41%

1952.HK

1952.HK • China

29.6 HKD

1.33B USD 1Y -47.1%

2595.HK

2595.HK • China

28.6 HKD

1.4B USD 1Y -21%

688739.SS

688739.SS • China

LIAONING CHENGDA BIOTECHNOLOGY

21.2 CNY

1.32B USD 1Y -21.9%

002030.SZ

002030.SZ • China

6.03 CNY

1.27B USD 1Y -6.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Website

https://www.kangh.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

48.4% p.a.

Max Drawdown (5Y)

-75.3%

Sharpe Ratio (5Y)

-0.36

Beta Factor

0.39

Size Class

Mid Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (48.4% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -75.3% in the extended horizon.